An overview of Compassionate Use Programs in the European Union member states-Reference-Cited by-同舟云学术

An overview of Compassionate Use Programs in the European Union member states

Published:2016 Issue:4 Volume:5 Page:244-254
ISSN:2186-361X
Container-title:Intractable & Rare Diseases Research
language:en
Short-container-title:IRDR

Author:

Balasubramanian Gayathri¹,Morampudi Suman¹,Chhabra Pankdeep¹,Gowda Arun¹,Zomorodi Behsad²

Affiliation:

1. FSRC, Part of phamax

2. Phamax AG

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/irdr/5/4/5_2016.01054/_pdf

Reference94 articles.

1. 1. Rahbari M, Rahbari NN. Compassionate use of medicinal products in Europe: Current status and perspectives. Bull World Health Organ. 2011; 89:163.

2. 2. Patil S. Early access programs: Benefits, challenges, and key considerations for successful implementation. Perspect Clin Res. 2016; 7:4-8.

3. 3. Global Genes. RARE Diseases: Facts and Statistics. https://globalgenes.org/rare-diseases-facts-statistics/ (accessed June 16, 2016).

4. 4. Howes M. Compassionate use and the impact on clinical research. http://www.centerwatch.com/news-online/2016/04/11/compassionate-use-impact-clinical-research/ (accessed June 16, 2016).

5. 5. Shire. Shire's Position on Offering Compassionate Use to Investigational Medicines. https://www.shire.com/who-we-are/how-we-operate/policies-and-positions/compassionate-use (accessed August 11, 2016).

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Early Access and the Potential Cost Savings by the Compassionate Use of Onco-haematological Drugs: Results from the Italian Study Compass-O;Clinical Drug Investigation;2024-07-20

2. A Qualitative Interview Study on Expanded Access Clinical Trials for Compassionate Use in Japan;Patient Preference and Adherence;2024-07

3. The impact of expanded access programs for systemic anticancer therapy in an Irish cancer centre;Irish Journal of Medical Science (1971 -);2024-05-28

4. Optimising oncology drug expenditure in Ireland;Irish Journal of Medical Science (1971 -);2024-04-03

5. Differences in time to patient access to innovative cancer medicines in six European countries;International Journal of Cancer;2023-10-20